How are Integrated Drug Discovery (IDD) services different from typical standalone services, such as chemistry or biology FTEs or FFS projects?
When running standalone services such as chemistry and DMPK at BioDuro-Sundia, then by default these services are always firewalled and no structures or data are ever shared between the two teams, and we never ask what the target is or if these compounds belong to the same project. We execute both completely separately unless a client explicitly instructs us otherwise.
However, when we talk about integration, then materials and data are shared between service lines on a restricted need-to-know basis, to enable both intellectual input and faster turnaround times.
However, to achieve the full benefits of a true IDD project, at a minimum 3 services - synthetic chemistry, biology, and DMPK - need to be run together and data and materials shared between them so that handoffs are optimized, decisions can be made quickly, and cycle times are reduced.
This exclusive interview with seasoned drug discovery researcher and industry veteran Frank Ruebsam, SVP Integrated Services of BioDuro-Sundia, includes many key takeaways for biotech and pharma companies considering outsourcing entire drug discovery projects to an IDD Service provider.
Key Interview Takeaways Include:
What exactly does Integrated Drug Discovery (IDD) mean and how is it different from standalone services?
What are the advantages of running IDD projects at BioDuro-Sundia?
What are some of the key factors to consider when choosing a service provider to run IDD projects?
What measures are in place to protect the sensitive IP generated during execution of an IDD project?
Download the PDF
We can engage clients at any stage, starting with early hit identification and hit services, or starting with late lead de-risking and forward-thinking backup strategies. Access a full range of discovery services under one roof from Hit ID to PCC.